Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 8
Key Considerations for Selection of ctDNA Detection Methods
Key opinion leaders evaluate the selection of available assays and platforms in relation to specific clinical objectives.
- How do you choose from the available assays/platforms based on your clinical objectives and desired information?
- What criteria or considerations guide your selection?
Recent Videos
Related Content
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024Article
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
